NCT06016036View on ClinicalTrials.gov

SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

October 8, 2021

Study Completion Date

February 21, 2022

Conditions
Renal Anemia in Non-dialysis Chronic Kidney Disease
Interventions
DRUG

SAL-0951

"SAL-0951：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"

DRUG

Placebo

"SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"

Trial Locations (1)

519041

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY

NCT06016036 - SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease | Biotech Hunter | Biotech Hunter